Drug companies are continuing in making dollars even 1.5 years after the eruption of a pandemic virus. World Health Organization (WHO) warns cases and deaths increasing in European nations. Some noted healthcare companies are involved to earn money as much as they can. WHO predicts that the EU continent could experience half a million deaths in the coming three months. When the first wave was really severe, many opined that remdesivir should make difference to combat coronavirus. During the COVID-19 pandemic, remdesivir was approved or authorized for emergency use to treat COVID‑19 in around 50 countries. The first oral tablet was developed for the treatment of symptomatic COVID-19 patients.
Now, the new game-changer “Molnupiravir” is going to hit the market. EU registered a 55% rise in COVID-19 cases despite the availability of vaccines. All these were giving boosters and preventing the human body to get infected. Till now no pharmacy company found a permanent solution for coronavirus. The United Kingdom approves oral pill Molnupiravir to treat coronavirus which has been developed by US-based Merck. The UK is the first nation in the world to approve the coronavirus antiviral pill. It has agreed to buy 480k courses with the first deliveries expected in November. The US also gave advance payment for the purchase of 1.7 million of the pill. It is also similar to earlier vaccines in giving a boost to the fight against the covid-19 pandemic. The only difference is earlier vaccines are injected into the human body through a needle but Molnupiravir is an oral one to take.
Health officials said that the pill will initially give to both vaccinated and unvaccinated patients. Patients would use the oral pill within 5 days of symptoms developing to be most effective. The pill was initially developed to treat flu. There are persistent side-effect concerns with mutagenic molnupiravir. The pill would reduce the risk of hospitalization or death by about half. Merck said that no deaths were reported after the treatment with Molnupiravir pill. Pfizer says antiviral pills cut the risk of severe COVID-19 by 89%. Merck seeks FDA authorization for the coronavirus treatment pill. It says that the treatment is likely to be effective against new variants of the virus.
Comments